

**VERSION OF SPECIFICATION PAGES WITH MARKINGS TO
SHOW CHANGES MADE**

- 1 -

P0136

**METHOD FOR TREATMENT OF [MULTIPLE SCLEROSIS AND
RELATED] NEURODEGENERATIVE DISEASES AND EFFECTS OF AGING**

BACKGROUND

a. Field of the Invention

The present invention relates generally to methods for the treatment of neurological conditions, and, more particularly, to a method for alleviating/controlling symptoms associated with neurodegeneration and similar conditions stemming from multiple sclerosis, aging, autoimmune diseases and other causes, by administration of compositions which induce an increased presence of histamine H2 and cyclic AMP in the body.

b. Related Art

Neurodegenerative conditions, which include diseases of autoimmunity, strike an increasing number of individuals each year, and for many of these conditions conventional treatments offer little in the way of true relief. In some instances, the neurodegenerative conditions are more or less specifically associated with a particular disease, such as multiple sclerosis, while in other instances the conditions are associated more generally with aging or some other condition or process of the body, such as a genetic disorder or an autoimmune disease, fibromyalgia, for example. As a group, however, these conditions are characterized by weakness and impaired physical functions, and, sometimes, impaired mental functions as well. Debilitation is often progressive, and, as stated, conventional treatments and therapies have been limited in their success.

For purposes of illustration the invention will be described below largely in the context of multiple sclerosis, which is a condition to which the invention has particular applicability; however, it will be understood that the present invention is applicable to neurodegenerative conditions, including autoimmune diseases, fibromyalgia, having any of a variety of sources, therefore it is not limited in scope to the treatment of multiple sclerosis alone.

SUMMARY OF THE INVENTION

The present invention addresses the problems cited above, and is a method for treatment of neurodegenerative disease conditions stemming from multiple sclerosis, aging, autoimmune diseases, and fibromyalgia, the method broadly comprising the step of administering to a patient a compound effective to increase neuronal metabolism of histamine to a histamine H₂-agonist, in an amount sufficient to stimulate production of cyclic AMP at a level which is sufficient to maintain myelin against undergoing self-degeneration.

The method may further comprise the step of selecting the compound from the group consisting of histamine N-methyltransferase, monoamine oxidase-A, monoamine oxidase-A agonists[, monoamine oxidase-B inhibitors,] and histamine H₃ antagonists[, and chelating agents].

The compound may comprise histamine N-methyltransferase, and the step of administering the compound may comprise administering histamine N-methyltransferase to the patient so as to increase neuronal metabolism of histamine to tele-methylhistamine. The step of administering N-methyltransferase may comprise administering isolated N-methyltransferase by injection.

In another embodiment, the compound may be monoamine oxidase-A, and the step of administering the compound may comprise administering monoamine oxidase-A to the patient so as to increase neuronal metabolism of tele-methylhistamine to an H₂ agonist such as 4-methylhistamine.

In another embodiment, the compound may be a monoamine oxidase-A agonist, and the step of administering the compound may comprise administering the monoamine oxidase-A agonist to the patient so as to increase neuronal metabolism of tele-methylhistamine to an H₂ agonist such as 4-methylhistamine. The monoamine oxidase-A agonist may be reserpine, and the step of administering the monoamine oxidase-A agonist may comprise administering reserpine by slow-release transdermal dose. Alternatively, the step of administering the monoamine oxidase-A agonist may comprise administering reserpine by injection, preferably in the range from about 1-10 mg/kg S.C. per day.

[In another embodiment, the compound may be a monoamine oxidase-B inhibitor, and

(continued)

the step of administering the compound may comprise administering the monoamine oxidase-B inhibitor to the patient so as to increase the activity ratio of monoamine oxidase-A to monoamine-oxidase-B so as to inhibit neuronal metabolism of tele-methylhistamine to R-alpha-methylhistamine and thereby increase neuronal metabolism of the tele-methylhistamine to 4-methylhistamine. The monoamine oxidase-B inhibitor may be selegiline hydrochloride.]

In another embodiment, the compound may be a histamine H₃ antagonist, and the step of administering the compound may comprise administering a histamine H₃ antagonist to the patient so as to inhibit neuronal metabolism of tele-methylhistamine to an H₃ agonist such as R-alpha-methylhistamine and thereby increase neuronal metabolism of tele-methylhistamine to an H₂ agonist such as 4-methylhistamine. The histamine H₃ antagonist may be thioperamide maleate.


[In another embodiment, the compound may be a chelating agent, and the step of administering the compound may comprise administering the chelating agent to the patient so as to reduce the presence of a predetermined iron constituent and thereby reduce peroxidation-induced inhibition of neuronal metabolism of histamine to tele-methylhistamine. The chelating agent may be deferoxamine mesylate, and the step of administering the chelating agent may comprise administering the deferoxamine mesylate in a range from about 500 mg-1 g IM per day. Alternatively, the step of administering the chelating agent may comprise administering the deferoxamine mesylate in a range from about 20-40 mg/kg S.C. per day.]

These and other features and advantages of the present invention will be apparent from a reading of the following detailed description.

It is hypothesized from the above data (indicating that those individuals having the lowest histamine levels demonstrated the most improvement) that the underlying problem is not in the supply of histamine to the neurons, but instead may be in the ability of the neurons to effectively metabolize histamine into histamine H₂.

To illustrate this, Table C shows the sequential steps in the production and metabolism of histamine to yield histamine H₂.

TABLE C



As can be seen, histamine is synthesized initially from L-histidine by the enzyme histidine decarboxylase. The histamine is stored in mast cells in the blood and most tissues in the body. Histamine that is released from mast cells results in an allergic response.

Histamine outside the brain is converted to imidazoleacetic acid by diamine oxidase (histaminase) (Ganong, Review of Medical Physiology, 6th Ed., 1973, pp.185-86). Histamine in the brain is mostly methylated by histamine N-methyltransferase to form tele-methylhistamine. Monoamine oxidase metabolizes the tele-methylhistamine further into R-alpha methylhistamine (an H₃ agonist)[,] and 4-methylhistamine (an H₂ agonist) [, and 2-methylhistamine (an H₁ agonist)] (Oishi, "Turnover of brain histamine and its changes by various drugs", Nippon Yakurigaku Zasshi, Nov 1988, 92:271-81).

Research shows that the histamine level in the cerebral spinal fluid of MS patients is 60% higher than that of controls, while the activity of histamine N-methyltransferase (HMT) is significantly lower than that of controls, tending to confirm that MS patients have an impaired histamine metabolism (Tuomisto et al, "Histamine and histamine-N-methyltransferase in the CSF of patients with multiple sclerosis", 1983). This is congruent with the findings from the study referred to above (which used an H₂ agonist and a phosphodiesterase inhibitor), in which 100% of the study subjects in the placebo group showed an overall increase in their whole blood histamine levels in the first 30 days. This elevated level of whole blood histamine persisted for the entire 90-day study in 80% of the placebo subjects (who did not receive the histamine H₂ agonist), and was probably due to the skin irritation caused by the citric acid placebo and transdermal patch. 95% of the verum group also experienced an elevation in their whole blood histamine in the first 30 days, but unlike the placebo group, for 80% of those showing initially elevated histamine levels, it was followed by a decrease in whole blood histamine. Those patients whose whole blood histamine level increased and then decreased the most significantly, experienced the most improvements in the symptoms tested.

These phenomena may be explained in that an H₂ agonist, such as that administered in the study, may decrease the histamine level by stimulating the Histamine N-methyltransferase activity. For example, in a study by Maroi et al ("Effect of reserpine on histamine metabolism in the mouse brain", Mar 1991, 256:967-72), reserpine, which can stimulate H₂ receptors, inhibited the histamine increase induced by a histamine N-methyltransferase inhibitor, while having no significant affect on a histidine decarboxylase inhibitor. Consequently, it is believed that the histamine H₂ agonist administered during the study caused the HMT system to increase HMT activity and thereby increase the metabolism of histamine, resulting in the observed decrease in whole blood histamine levels.

Therefore, based on the results of the 29-patient study and other research, it is postulated that an altered histamine metabolism is associated with MS and related neurodegenerative conditions, resulting in a decrease in the turnover of histamine, and therefore lower histamine H₂ levels, leading ultimately to inadequate cAMP production. This view is consistent with the results of the Tuomisto study referenced above, which showed that the histamine level in MS patients was 60% higher than in non-MS patients while the activity of the enzyme, HMT, was significantly lower than in controls.

The study results set forth above also suggest that the problem with the metabolism of histamine in MS patients probably does not lie in the histidine decarboxylase enzyme activity, but rather in the activity of HMT or the monoamine oxidase enzymes, since it is clear the MS patients in the study were capable of producing whole blood histamine. MS patients are therefore apparently able to produce histamine from L-histidine via the enzymatic activity of histidine decarboxylase, but further metabolism of histamine in the neurons is impaired. This impaired neuron histamine metabolism may be due to either inadequate HMT activity or impaired MAO activity, or possibly both.

i. HMT Activity

Inadequate HMT activity may be the result of impaired synthesis of the enzyme. Based on this etiology, HMT levels may be beneficially supplemented by administration of the compound itself, i.e., by injections or other administration of the HMT enzyme. For example, HMT isolated as described in U.S. Patent No. 4,769,322 (to Eli Lilly & Co.) may be administered parenterally, such as by intramuscular or subcutaneous injections, and possibly via transdermal application or oral administration.

[Inadequate HMT activity may also be due to some factor inhibiting the action of HMT. In particular, it is believed that unbound iron may be an agent in the inhibition of HMT. For example, research has shown that iron-dependent peroxidation will inhibit HMT activity by 40%. (Rafalowska & Walajtys, "Peroxidation-induced changes of histamine metabolism and transport of its precursor histidine in rat brain synaptosomes", Free Radic Biol Med, 1991, 10:23-28). MS patients are also known to have iron deposits in the brain and in the tissue surrounding the plaques (LeVine, "Iron deposits in multiple sclerosis and Alzheimer's disease brains", Brain Res,)]

ii. MAO activity

As explained above, reduced metabolism of histamine may also be the result of impaired monoamine oxidase (MAO) activity.

Inadequate activity of monoamine oxidase-A and/or monoamine oxidase-B can result in an accumulation of [telemethylhistamine] tele-methylhistamine, which in turn causes an inhibition of HMT and an accumulation of histamine. As can be seen in Table C, tele-methylhistamine is primarily metabolized via monoamine oxidase B (MAO-B) into an H₃ agonist (R-alpha-methylhistamine) (Elsworth et al, "Tele-methylhistamine is a specific MAO-B substrate in man", Psychopharmacology, 1980, 69:287-90). [R-alpha-methylhistamine is an H₃ agonist.] The release of histamine is regulated by H₃ autoreceptors (Prast et al., "In vivo modulation of histamine release by autoreceptors and muscarinic acetylcholine receptors in the rat anterior hypothalamus", Naunyn Schmiedeberg's Arch Pharmacol, Dec 1994, 350:599-604). Tele-methylhistamine is metabolized by a second path into an H₂ agonist (4-methylhistamine) [(the H₂ agonist)], via monoamine oxidase A (MAO-A). Hence, the relative amounts of H₂ and H₃ agonists produced depends primarily on the relative activity of the MAO-A and MAO-B metabolic paths.

The MAO-A:MAO-B activity ratio is genetically encoded on the X chromosome (Garpenstrand et al, "Platelet monoamine oxidase activity is related to MAOB intron 13 genotyp", J. Neural Transm, 2000, 107:523-30). Interestingly, MS is more predominant in females than males. Estrogen and aging also selectively affect the synthesis of MAO-A. Estrogen decreases MAO-A activity in the hypothalamus, but does not affect the activity of MAO-B (Edelstein & Breakefield, "Monoamine oxidases A and B are differentially regulated by glucocorticoids and "aging" in human skin fibroblasts", Cell Mol Neurobiol, Jun 1986, 6:121-50). The MAO-A:MAO-B activity ratios also decrease in all regions of the brain during maturational development in rats, and research has shown that the ontogenetic development of MAO-A and MAO-B in the human brain is parallel to that observed in the rodent brain (Strolin et al, "Developmental aspects of the monoamine-degrading enzyme monoamine oxidase", Dev Pharmacol Ther, 1992, 18:191-200).

As the MAO-A:MAO-B activity ratio decreases, metabolism of tele-methylhistamine via MAO-B becomes more dominant and MAO-A activity is inhibited. Elevated activity of MAO-B is associated with neurodegenerative disorders such as Parkinson and Alzheimer's diseases

(Carlo et al, "Monoamine oxidase B expression is selectively regulated by dexamethasone in cultured rat astrocytes", *Brain Res*, Mar 1996, 4:175-83). Inhibition of MAO-A activity also results in a significant decrease in the responsiveness of the noradrenergic cyclic AMP generating system (Mishra et al, "Effect of selective monoamine oxidase inhibition by clorgyline and deprenyl on the norepinephrine receptor-couple adenylate cyclase system in rat cortex", *Psychopharmacology*, 1983, 81:220-3). The H₂ agonist (4-methylhistamine) [, the H₂ agonist,] is the metabolite of tele-methylhistamine via MAO-A and is a potent stimulator of cyclic AMP synthesis. Thus, a decrease in MAO-A activity results in decreased H₂ receptor stimulation, which results in decreased cAMP production. As stated above, deficient cAMP production is believed to be directly involved in demyelination in MS and similar neurodegenerative conditions.

Other contributors to MAO-A inhibition may include stress. It is known that exacerbations or worsening of symptoms in MS patients are often triggered by stress. Research shows that stress stimulates the release of endogenous MAO-A inhibitors (Glover, "Function of endogenous monoamine oxidase inhibitors (tribulin), *J Neural Transm Suppl*, 1998, 52:307-13). Stress may thus be an added factor in the endogenous inhibition of an already deficient activity of MAO-A.

Lipid peroxidation is also known to inhibit the monoamine oxidase system (Medvedev et al, "The role of lipid peroxidation in the possible involvement of membrane-bound monoamine oxidases in gamma-aminobutyric acid and glucosamine deamination in rat brain. Focus on chemical pathogenesis of experimental audiogenic epilepsy", *Mol Chem Neuropathol*, Feb-Apr 1992, 16:187-201). MS patients have low levels of copper and zinc as discussed earlier, which debilitates the Cu-Zn-superoxide dismutase enzyme. Inhibition of this enzyme results in an increase in superoxide and nitric oxide which results in the formation of peroxinitrites, a free radical that leads to myelin destruction in MS (Johnson, "The possible role of gradual accumulation of copper, cadmium, lead and iron and gradual depletion of zinc, magnesium, selenium, vitamins B2, B6, D, and E and essential fatty acids in multiple sclerosis", Sep 2000, 55:239-41). Deficient levels of copper in MS patients also interferes with the synthesis of the monoamine oxidases themselves, because they are copper-containing enzymes.

A decrease in MAO-A activity caused by one or more of the mechanisms described above will decrease the MAO-A:MAO-B ratio. The resulting disproportion of the MAO-

(continued)

A:MAO-B ratio results in a parallel disproportion in the production ratio of the H₂ agonist
(4-methylhistamine) to

the H₃ agonist (R-alpha-methylhistamine). Increased production of the H₃ agonist (R-alpha-methylhistamine) [, an H₃ agonist,] then further inhibits MAO-A activity, compounding the H₂ deficiency.

Inhibition of MAO-B activity would increase the MAO-A:MAO-B activity ratio, thereby increasing histamine H₂ levels. An H₃ antagonist such as thioperamide maleate inhibits MAO-B (Sakurai et al, "Effects of the histamine H₃ agonist (R)-alpha-methylhistamine and the antagonist thioperamide in vitro on monoamine oxidase activity in the rat brain", Exp Clin Pharmacol, Nov 1995, 17C:46-50). It may therefore be beneficial to administer an H₃ antagonist such a thioperamide maleate[, or an MAO-B inhibitor such as selegiline hydrochloride,] in order to increase the MAO-A:MAO-B activity ratio. Thioperamide maleate is available in suitable form from VWR Scientific Products, a company of the Merck Group. [Selegiline hydrochloride is available in suitable form from Somerset Pharmaceutical Company as Eldepryl® (which has been utilized in connection with Parkinson's disease and Alzheimer's disease). Eldepryl® or another MAO-B inhibitor may suitably be administered via a slow release transdermal application, in a dosage sufficient to inhibit MAO-B but not so high as to affect the MAO-A activity (in order to avoid the accumulation of tyramine). The MAO-B inhibitor may also be administered orally, for example, at a dosage of about 10 mg per day for a patient of average body weight.]

[Still further, i]It may also be beneficial to administer MAO-A agonists such as reserpine. Reserpine oxidizes serotonin and is therefore similar in action to MAO-A, since MAO-A also oxidizes serotonin (Benedetti & Keane, "Differential changes in monoamine oxidase A and B activity in the aging rat brain", J Neurochem, Nov 1980, 35:1026-32). Injecting reserpine in dosages of about 1-10 mg/kg S.C. per day, or using a slow release transdermal dose, will be sufficient in most instances to increase the metabolism of tele-methylhistamine to 4-methylhistamine, resulting in adequate H₂ receptor stimulation. Reserpine is available in suitable form from VWR Scientific Products.

It is to be recognized that various alterations, modifications, and/or additions may be introduced into the constructions and arrangements of parts described above without departing from the spirit or ambit of the present invention.

REMARKS**a. Response to Claim Rejections**

In the Office Action, claims 1, 2, 6, 7 and 10-13 were rejected under 35 USC §§102 and/or 103. Claims 3-5, 8, 9 and 14-17 were objected to as being dependent upon the rejected base claim, but were stated to be allowable if rewritten in independent form including all of the limitations of the base claim and in any intervening claims.

Accordingly, Applicant has amended claim 1 to correspond to claim 3 amended to include all of the elements of the base claim and the intervening claim (claim 2). Claim 3 has consequently been cancelled and claim 4 has been amended to depend from claim 1.

New claim 18 corresponds to claim 5 rewritten in independent form including all of the limitations of the base claim and intervening claims, except that, in order to avoid limitations unnecessary to distinguish over the prior art, the step of administering monoamine oxidase-A to the patient "so as to increase neuronal metabolism of tele-methylhistamine to 4-methylhistamine" has been amended to read "so as to increase metabolism of tele-methylhistamine to an H₂ agonist." Support for this amendment is provided at pages 25-26 and 29-30 of the specification. The references do not teach or suggest administering monoamine oxidase-A as remains required by claim 18.

New claim 19 similarly corresponds to claim 8 rewritten in independent form including the limitations of the base claim and intervening claims, except that, in order to avoid unnecessary limitations, "4-methylhistamine" has against been amended to read "H₂ agonist" and, furthermore, "R-alpha-methylhistamine" has been amended to read "an H₃ agonist"; support for the latter amendment is found at pages 25-26 of the specification. The references do not teach or suggest the step of administering a histamine H₃ antagonist as required by claim 19 and its dependent claim 20 (which corresponds to original claim 8).

New claim 21 corresponds to claim 14 rewritten in independent form including the limitations of the base claim and intervening claims, except that, for the reasons given above, "4-methylhistamine" has been amended to read "an H₂ agonist". The references do not teach or suggest the step of administering a monoamine oxidase-A agonist as required by claim 21 and its dependent claims 22-24 (which correspond to original claims 15-17).

It is therefore believed that all pending claims are now in condition for allowance.

b. Amendments to Title and Specification

The title has been amended to be more descriptive of the claimed subject matter.

Amendments have been made in the specification to improve the terminology and to delete matter not directly relating to the invention which is now claimed. Specifically, the order of the terms has been revised at several points to place the terms "H₂ agonist" and "H₃ agonist" before the respective examples "4-methylhistamine" and "R-alpha-histamine" in order to provide a clearer explanation of the processes that are described therein. A minor typographical error has also been corrected in the spelling of tele-methylhistamine.

TABLE C has similarly been amended to place the terms "H₂ agonist" and "H₃ agonist" uppermost, so as to more clearly illustrate the metabolic sequences that are shown thereby. TABLE C has also been amended to eliminate surplus matter concerning the H₁ receptor agonist which does not directly relate to the claimed invention.

Surplus language has also been deleted on pages 27-28, relating to iron chelation, and on page 31, relating to the use of an MAOA-B inhibitor, since the claims relating to this subject matter have been cancelled by the present amendment.

c. Conclusion


Applicant respectfully requests reconsideration of the present application in view of the amendments and remarks set forth herein. It is believed that the above-referenced claims are now in condition for allowance. If there is any matter that can be expedited by consultation with Applicant's attorney, such would be welcome. Applicant's attorney can normally be reached at the telephone number given below.

Signed at Bellingham, County of Whatcom, State of Washington this 28th day of January 2002.

Respectfully submitted,

ELAINE A. DELACK

By


Todd N. Hathaway, Reg. No. 32,991
119 N. Commercial St. #620
Bellingham, WA 98225-4437
(360) 647-1976

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date shown below.

1-28-02
Date

Dale Y Perez
(Print name of person mailing paper)

Dale Y Perez
(Signature of person mailing paper)